What does income taxes at U.S. statutory rate of 21% mean?

This represents the theoretical income tax expense calculated by applying the standard federal statutory tax rate to the company's pre-tax income or loss. It serves as the baseline figure in the effective tax rate reconciliation process. This allows investors to compare the company's actual tax burden against the standard statutory benchmark.

Bicara Therapeutics BCAX Income taxes at U.S. statutory rate of 21%

Income taxes at U.S. statutory rate of 21% at other companies

Kyndryl HoldingsKD

21%0.0pp

CarGurus, Inc.CARG

21%0.0pp

ALH

Alliance Laundry Holdings Inc.ALH

21%0.0pp

Option Care Health, Inc.OPCH

21%0.0pp

AbCellera Biologics Inc.ABCL

27%0.0pp

Allison Transmission HoldingsALSN

21%0.0pp

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.68B+81.4%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.

The official record: Bicara Therapeutics’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's income taxes at u.s. statutory rate of 21%.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's income taxes at U.S. statutory rate of 21%?: Bicara Therapeutics (BCAX) reported income taxes at U.S. statutory rate of 21% of 21% in Q4 2025.
What does income taxes at U.S. statutory rate of 21% mean?: This represents the theoretical income tax expense calculated by applying the standard federal statutory tax rate to the company's pre-tax income or loss. It serves as the baseline figure in the effective tax rate reconciliation process. This allows investors to compare the company's actual tax burden against the standard statutory benchmark.